Martin Shkreli Says on Twitter He May Testify on Drug Prices

  • Former Turing CEO took the Fifth last time he visited Congress
  • Executive says he has ‘lots of insight’ into price controversy

Martin Shkreli.

Photographer: John Taggart/Bloomberg

Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, may appear before Congress to testify on drug pricing.

The outspoken executive, who set off a firestorm of criticism after buying an old anti-parasitic drug and raising the price to $750 a pill from $13.50, agreed to testify before the House Committee on Oversight and Government Reform, according to an e-mailed statement from the office of Representative Elijah Cummings of Maryland, the top Democrat on the committee.

Shkreli previously appeared before Congress in February and decided to invoke the Fifth Amendment, frustrating lawmakers.

He seemed to change his mind on Thursday in a conversation on the social media platform Twitter, where he wrote, “Any chance I can come through this time and actually testify?” in response to the House Oversight Committee saying it wanted a hearing with Mylan NV officials on its price increases for EpiPens.

“Will you testify?” the committee tweeted to Shkreli.

“I think we can work it out,” he responded. “I have a lot of insight and some potential solutions for these issues.”

In a later Twitter post, Shkreli added that “we haven’t agreed on anything yet -- I’ll be in touch.”

Shkreli declined to comment when reached by e-mail.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE